• Home
  • NEW DAY MEDICINE
  • 2(40)2022
  • 118 -2 (40) 2022 — Abdurakhmanova N.M. — PECULIARITIES OF IMMUNE STATUS IN PATIENTS WITH ANKYLOSING SPONDYLOARTHRITIS AFTER COVID-19

118 -2 (40) 2022 — Abdurakhmanova N.M. — PECULIARITIES OF IMMUNE STATUS IN PATIENTS WITH ANKYLOSING SPONDYLOARTHRITIS AFTER COVID-19

PECULIARITIES OF IMMUNE STATUS IN PATIENTS WITH ANKYLOSING SPONDYLOARTHRITIS AFTER COVID-19

Abdurakhmanova N.M. Tashkent Medical Academy 

Resume

The article presents data from our own studies on the study of the state of the immune status in patients with ankylosing spondylitis who had COVID-19. In patients, a detailed immunogram was studied, as well as scales of disease activity. According to the results of the research, a sharp suppression of the cellular link of the immune system was revealed in patients with ankylosing spondylitis who underwent COVID-19, compared with the group without caronavirus infection.

Keywords: immune status, COVID-19, ankylosing spondylitis

First page

592

Last page

594

For citation: Abdurakhmanova N.M. PECULIARITIES OF IMMUNE STATUS IN PATIENTS WITH ANKYLOSING SPONDYLOARTHRITIS AFTER COVID-19 //New Day in Medicine 2(40)2022 592-594 https://clck.ru/eddsZ

LIST OF REFERENCES:

  1. Ахмедов ХС. Особенности состояния иммунного статуса при ревматоидном артрите в зависимости от климатогеографических и экологических зон Узбекистана. //Научно-практическая ревматология. 2016;54(2):183-186.
  2. Курлаева Л. В., Степанова К. Б., Степанова Т. Ф., Кальгина Г. А., Григорьева С. А., Панина Ц. А., Сидоренко О. Н., Сиюткина О. Н., Семенюк Е. Н. 2020. Предварительные итоги изучения основных показателей иммунной системы у пациентов с новой коронавирусной инфекцией COVID-19. COVID19- PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111792
  3. Abdurakhmanova N.M. High concentration of tumor necrosis factor in ankylosing spondylitis patients after COVID-19. //British medical journal. Volume 1, No.1.1, January 2022
  4. Barnes B.J. et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps, //J. Exp. Med. 2020; 217 (6): e20200652. DOI: 10.1084/jem.20200652.
  5. Duan Z. et al. The immune dysfunction in ankylosing spondylitis patients. //BioScience Trends. 2017; 11(1):69-76.
  6. Gianfrancesco M.A., Hyrich K.L., Gossec L. et al. COVID-19 Global Rheumatology Alliance Steyering Committeye Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registriyes. //Lancet Rheumatol. 2020; 250–ye253. doi: 10.1016/S2665-9913(20)30095-3
  7. Mikuls T.R., Johnson S.R., Frayenkel L. et al. American College of Rheumatology guidance for the management of adult patiyens with rheumatic disease during the COVID-19 pandemic. //Arthritis Rheumatol. 2020 doi:10.1002/art.41301.
  8. Ranganathan et al. Pathogenesis of ankylosing spondylitis — recent advances and future directions. Nature reviews. //Rheumatology. 2017. doi:10.1038/nrrheum.2017.56
  9. Schramm-Luc A. et al. Age determines response to anti-TNFα treatment in patients with ankylosing spondylitis and is related to TNFα-producing CD8 cells. //Clinical Rheumatology. https://doi.org/10.1007/s10067-018-4061-y
  10. Yang et al. TNF-α inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitis. //Arthritis Research & Therapy (2020) 22:149. https://doi.org/10.1186/s13075-020-02226-8

file

download